Maitake for Integrative Cancer Care
ConditionCancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorThe Canadian College of Naturopathic Medicine
About this trial
Maitake is an edible mushroom that is used for both its nutritional and medicinal properties. Human and animal studies have shown Maitake may help improve immune function; however, its effectiveness in people with cancer is not clear. The investigators aim to measure if Maitake has any immunomodulatory effects when given alongside conventional systemic cancer therapy.
Eligibility criteria
Qualifiers
Adults (≥18 years of age)
Confirmed cancer diagnosis through biopsy or radiologic imaging
Undergoing systemic treatment with either chemotherapy or CD4/6 inhibitors
Currently receiving cancer treatment in Ontario, Canada
Disqualifiers
Hematologic cancers
Previously received any mushroom supplement within 6 months prior to enrolment
Allergy to mushrooms or mushroom products
Diagnosis of diabetes
Trial design
Treatments tested in this trial
- Black Maitake Prothera
Treatment groups
40 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov